-transparent.png){kind=logo}
We sought to determine the potential of infecting lymphoid cells from patients with chronic leukemia (CLL) with Epstein-Barr virus (EBV) by testing for EBV receptors (EBVR) by flow cytometry, assessing for infectability of these cells by culturing with B95-8-derived virus, and staining for EB nuclear-associated antigens (EBNA) at various times post-infection. EBVR were present on 54-91% of lymphoid cells in seven cases of CLL and on 46% of prolymphocytic leukemia cells. Dynamic changes regarding EBNA positivity, morphology, and viability occurred post-infection with the virus. On day 2 only a few EBNA-positive lymphoblasts were observed. On days 11-21 positivity increased from 2 to 34% of cells. Simultaneously, the viable cell number declined to approximately 1/10th of original number. A significant proportion of the EBNA-positive cells corresponded to the original CLL cells. In 3 of 7 cases of CLL a Pan T-cell phenotype was demonstrated by Leu-1 monoclonal antibody testing. The infected cells did not react with two monoclonal antibodies, EBV-CS 1 and 4, which react with B-cell lymphoblastoid cell lines (B-LCL). Moreover, the B-LCL derived at 1-2 months post-infection of CLL cells did not express the Leu-1 antigen, but expressed EBV-CS 1 or 4 defined antigens. In the prolymphocytic leukemia, 64% of the cells showed EBNA positivity on day 7 and giant cells with huge round or multiple nuclei appeared which were EBNA-positive. CLL and prolymphocytic leukemia cells can be infected as demonstrated by EBNA-positivity. This infection does not lead to immediate transformation, but evokes lymphoblast and multinucleated giant cell production prior to the death of cells.
E Tatsumi, and
S Harada, and
T Bechtold, and
H Lipscomb, and
J Davis, and
C Kuszynski, and
D J Volsky, and
T Han, and
J Armitage, and
D T Purtilo
February 1987,
Hawaii medical journal,
E Tatsumi, and
S Harada, and
T Bechtold, and
H Lipscomb, and
J Davis, and
C Kuszynski, and
D J Volsky, and
T Han, and
J Armitage, and
D T Purtilo
November 1971,
International journal of cancer,
E Tatsumi, and
S Harada, and
T Bechtold, and
H Lipscomb, and
J Davis, and
C Kuszynski, and
D J Volsky, and
T Han, and
J Armitage, and
D T Purtilo
June 1988,
International journal of cancer,
E Tatsumi, and
S Harada, and
T Bechtold, and
H Lipscomb, and
J Davis, and
C Kuszynski, and
D J Volsky, and
T Han, and
J Armitage, and
D T Purtilo
February 1994,
Leukemia,
E Tatsumi, and
S Harada, and
T Bechtold, and
H Lipscomb, and
J Davis, and
C Kuszynski, and
D J Volsky, and
T Han, and
J Armitage, and
D T Purtilo
January 2016,
Oncotarget,
E Tatsumi, and
S Harada, and
T Bechtold, and
H Lipscomb, and
J Davis, and
C Kuszynski, and
D J Volsky, and
T Han, and
J Armitage, and
D T Purtilo
November 2010,
Infectious agents and cancer,
E Tatsumi, and
S Harada, and
T Bechtold, and
H Lipscomb, and
J Davis, and
C Kuszynski, and
D J Volsky, and
T Han, and
J Armitage, and
D T Purtilo
August 1993,
The American journal of surgical pathology,
E Tatsumi, and
S Harada, and
T Bechtold, and
H Lipscomb, and
J Davis, and
C Kuszynski, and
D J Volsky, and
T Han, and
J Armitage, and
D T Purtilo
April 2001,
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
E Tatsumi, and
S Harada, and
T Bechtold, and
H Lipscomb, and
J Davis, and
C Kuszynski, and
D J Volsky, and
T Han, and
J Armitage, and
D T Purtilo
June 1997,
International journal of cancer,
E Tatsumi, and
S Harada, and
T Bechtold, and
H Lipscomb, and
J Davis, and
C Kuszynski, and
D J Volsky, and
T Han, and
J Armitage, and
D T Purtilo
June 2013,
The Journal of dermatology,
